FDA Expands Approval of Spiriva Respimat (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

RIDGEFIELD, Conn., February 16, 2017 - Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat for the long-term, once-daily maintenance treatment of asthma in people age...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news